Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
2.100
-0.040 (-1.87%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Kyverna Therapeutics Stock Forecast
KYTX's stock price has decreased by -88.14% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Kyverna Therapeutics stock have an average target of 18.8, with a low estimate of 4.00 and a high estimate of 33. The average target predicts an increase of 795.24% from the current stock price of 2.10.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Kyverna Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $6 → $4 | Hold | Maintains | $6 → $4 | +90.48% | Apr 3, 2025 |
Morgan Stanley | Morgan Stanley | Buy Maintains $40 → $20 | Buy | Maintains | $40 → $20 | +852.38% | Apr 1, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +185.71% | Nov 20, 2024 |
Wells Fargo | Wells Fargo | Buy Maintains $44 → $24 | Buy | Maintains | $44 → $24 | +1,042.86% | Nov 15, 2024 |
UBS | UBS | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +519.05% | Oct 10, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.97
from -3.33
EPS Next Year
-3.55
from -3.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | n/a | 4.5M | ||
Avg | n/a | n/a | 1.9M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -3.63 | -1.63 | -3.39 | ||
Avg | -3.97 | -3.55 | -4.27 | ||
Low | -4.11 | -4.21 | -4.64 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.